Detail akcie Aptevo Therptcs Rg online

Business Summary: Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel bispecific immunotherapies for the treatment of cancer. The Company has two clinical candidates: Mipletamig and ALG.APV-527. Mipletamig is being evaluated in RAINIER, a two-part Phase 1b/2 trial for the treatment of frontline acute myeloid leukemia in combination with standard-of-care venetoclax + azacitidine. Mipletamig has received orphan drug designation for AML according to the Orphan Drug Act. ALG.APV-527, a bispecific conditional 4-1BB agonist, only active upon simultaneous binding to 4-1BB and 5T4, is being co-developed with Alligator Bioscience and is being evaluated in a Phase 1 clinical trial for the treatment of multiple solid tumor types likely to express 5T4. The Company has three pre-clinical candidates with different mechanisms of action designed to target a range of solid tumors. All pipeline candidates are created from two proprietary platforms, ADAPTIR and ADAPTIR-FLEX.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Aptevo Therapeutics Inc revenues was not reported. Net loss applicable to common stockholders increased 21% to $21.6M. Higher net loss reflects Other expense from continuing operations decrease of 61% to $155K (income). Basic Earnings per Share excluding Extraordinary Items increased from -$161226.35 to -$1773.00.